Jason Krikorian - 02 Oct 2024 Form 4 Insider Report for Augmedix, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 Oct 2024
Net transaction value: -$174,440
SEC form: 4
Accepted by SEC: 04 Oct 2024, 13:01:42 UTC
Prior SEC filing: 15 Aug 2024
Next SEC filing: 03 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Todd Holvick, Attorney-in-Fact

Key filing fact

Jason Krikorian filed Form 4 for Augmedix, Inc. on 04 Oct 2024.

Key facts

This page summarizes Jason Krikorian's Form 4 filing for Augmedix, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Oct 2024, 13:01.

Change

Previous filing in this sequence was filed on 15 Aug 2024.
Current net transaction value: -$174,440.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUGX transaction

Common Stock

Disposed to Issuer

Transaction value: $174,440
Shares: -74,230
Change %: -100%
Price: $2.35
Shares after: 0
Date: 02 Oct 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jason Krikorian is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings.